Zavation Medical Products Launches Cortical Screw – Latest Portfolio Addition

June 16, 2020

Zavation Medical Products has announced the launch of the Cortical Screw, a screw designed for use in the cortical bone as an extension of the Zavation Spinal System.

Zavation Medical Products notes the Cortical Screw is the latest addition to Zavation’s portfolio. The cortical screw is designed to achieve greater cortical bone purchase with a smaller midline incision when using Cortical Bone Trajectory (CBT). It comes in a variety of sizes to provide an optimized fit for each patient. It also includes a self-tapping feature on both sides of the tip and a 30 degree variable head angulation. This optimized fit allows for enhancement of structural stability while the thread design maximizes screw purchase. Standard and reduction screw options are offered and the reduction screw has a “break-off” tab available.

Dr. Graham Calvert, Orthopedic Spine Surgeon at Mississippi Sports Medicine, stated, “I am very excited about the new cortical screw technology from Zavation Medical Products. With 3 zones of variable thread pitch it is tailor-made for the cortical trajectory. The system is also extremely versatile with 4.5, 5.0, and 5.5mm diameter offerings. Overall it is the most compact, durable, and easy to implant cortical system on the market. I have been utilizing for over a year now with one hundred plus cases and have had no hardware failure.”

The Zavation Spinal System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of thoracic, lumbar, and sacral spine: degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; tumor; pseudoarthrosis; and failed previous fusion.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version